Novo Nordisk Stock Eyes Worst Day, Week on Record

Novo Nordisk A/S (NYSE:NVO) stock is down 18.9% to trade at $82.25 at last check, after the pharmaceutical company's weight loss drug CagriSema missed expectations of a late-stage study. The popularization of treatments such as Novo Nordisk's Ozempic, as well as Eli Lilly's (LLY) Zepbound for weight management caused quite the industry stir this year, with telehealth name Hims & Hers Health (HIMS) also joining the race.NVO is on track for its biggest daily and weekly percentage losses on record, as well as ...